source
- STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&AProving out a "synthetic lethality" approach can help treat cancer will take a lot more work. It also might trigger some creative deal-making.STAT · 1mo ago↗ source
- HHS responds coolly to paper on alcohol riskSoda and liver cancer, scientists conflicted on a new NIH proposal, and more health news from Morning RoundsSTAT · 1mo ago↗ source
- Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. Zasocitinib induce…Endpoints · 1mo ago↗ source